
This large population-based study developed and validated the CAMD score, a simple clinical tool for hepatocellular carcinoma risk stratification in patients with metabolic dysfunction-associated steatotic liver disease. Using nationwide data from Taiwan and external validation in Hong Kong, the model incorporates cirrhosis, age, sex, and diabetes to identify patients at high risk for HCC who may benefit from targeted surveillance strategies.
Like
Save
Share